These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 17546599)
1. Targeting the IGF-1R using picropodophyllin in the therapeutical 5T2MM mouse model of multiple myeloma: beneficial effects on tumor growth, angiogenesis, bone disease and survival. Menu E; Jernberg-Wiklund H; De Raeve H; De Leenheer E; Coulton L; Gallagher O; Van Valckenborgh E; Larsson O; Axelson M; Nilsson K; Van Camp B; Croucher P; Vanderkerken K Int J Cancer; 2007 Oct; 121(8):1857-61. PubMed ID: 17546599 [TBL] [Abstract][Full Text] [Related]
2. Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP: an in vitro and in vivo study in the 5T33MM mouse model. Menu E; Jernberg-Wiklund H; Stromberg T; De Raeve H; Girnita L; Larsson O; Axelson M; Asosingh K; Nilsson K; Van Camp B; Vanderkerken K Blood; 2006 Jan; 107(2):655-60. PubMed ID: 16046527 [TBL] [Abstract][Full Text] [Related]
3. Targeting the insulin-like growth factor-1 receptor by picropodophyllin for lung cancer chemoprevention. Zhang Q; Pan J; Lubet RA; Wang Y; You M Mol Carcinog; 2015 Jun; 54 Suppl 1():E129-37. PubMed ID: 25163779 [TBL] [Abstract][Full Text] [Related]
4. Control of apoptosis in human multiple myeloma by insulin-like growth factor I (IGF-I). Jernberg-Wiklund H; Nilsson K Adv Cancer Res; 2007; 97():139-65. PubMed ID: 17419944 [TBL] [Abstract][Full Text] [Related]
5. Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival. Croucher PI; De Hendrik R; Perry MJ; Hijzen A; Shipman CM; Lippitt J; Green J; Van Marck E; Van Camp B; Vanderkerken K J Bone Miner Res; 2003 Mar; 18(3):482-92. PubMed ID: 12619933 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of VEGF secretion and experimental choroidal neovascularization by picropodophyllin (PPP), an inhibitor of the insulin-like growth factor-1 receptor. Economou MA; Wu J; Vasilcanu D; Rosengren L; All-Ericsson C; van der Ploeg I; Menu E; Girnita L; Axelson M; Larsson O; Seregard S; Kvanta A Acta Ophthalmol; 2008 Nov; 86 Thesis 4():42-9. PubMed ID: 19032681 [TBL] [Abstract][Full Text] [Related]
7. Picropodophyllin inhibits tumor growth of human nasopharyngeal carcinoma in a mouse model. Yin SC; Guo W; Tao ZZ Biochem Biophys Res Commun; 2013 Sep; 439(1):1-5. PubMed ID: 23973483 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of VEGF secretion and experimental choroidal neovascularization by picropodophyllin (PPP), an inhibitor of the insulin-like growth factor-1 receptor. Economou MA; Wu J; Vasilcanu D; Rosengren L; All-Ericsson C; van der Ploeg I; Menu E; Girnita L; Axelson M; Larsson O; Seregard S; Kvanta A Invest Ophthalmol Vis Sci; 2008 Jun; 49(6):2620-6. PubMed ID: 18515591 [TBL] [Abstract][Full Text] [Related]
9. IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G2/M-phase accumulation and apoptosis in multiple myeloma cells. Strömberg T; Ekman S; Girnita L; Dimberg LY; Larsson O; Axelson M; Lennartsson J; Hellman U; Carlson K; Osterborg A; Vanderkerken K; Nilsson K; Jernberg-Wiklund H Blood; 2006 Jan; 107(2):669-78. PubMed ID: 16166596 [TBL] [Abstract][Full Text] [Related]
10. Oral picropodophyllin (PPP) is well tolerated in vivo and inhibits IGF-1R expression and growth of uveal melanoma. Economou MA; Andersson S; Vasilcanu D; All-Ericsson C; Menu E; Girnita A; Girnita L; Axelson M; Seregard S; Larsson O Acta Ophthalmol; 2008 Nov; 86 Thesis 4():35-41. PubMed ID: 19032680 [TBL] [Abstract][Full Text] [Related]
11. Insulin-like growth factor type-I receptor-dependent phosphorylation of extracellular signal-regulated kinase 1/2 but not Akt (protein kinase B) can be induced by picropodophyllin. Vasilcanu R; Vasilcanu D; Sehat B; Yin S; Girnita A; Axelson M; Girnita L Mol Pharmacol; 2008 Mar; 73(3):930-9. PubMed ID: 18070930 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of p38alpha mitogen-activated protein kinase prevents the development of osteolytic bone disease, reduces tumor burden, and increases survival in murine models of multiple myeloma. Vanderkerken K; Medicherla S; Coulton L; De Raeve H; Willems A; Lawson M; Van Camp B; Protter AA; Higgins LS; Menu E; Croucher PI Cancer Res; 2007 May; 67(10):4572-7. PubMed ID: 17495322 [TBL] [Abstract][Full Text] [Related]
13. Multifunctional role of matrix metalloproteinases in multiple myeloma: a study in the 5T2MM mouse model. Van Valckenborgh E; Croucher PI; De Raeve H; Carron C; De Leenheer E; Blacher S; Devy L; Noël A; De Bruyne E; Asosingh K; Van Riet I; Van Camp B; Vanderkerken K Am J Pathol; 2004 Sep; 165(3):869-78. PubMed ID: 15331411 [TBL] [Abstract][Full Text] [Related]
14. The HDAC inhibitor LBH589 enhances the antimyeloma effects of the IGF-1RTK inhibitor picropodophyllin. Lemaire M; Fristedt C; Agarwal P; Menu E; Van Valckenborgh E; De Bruyne E; Österborg A; Atadja P; Larsson O; Axelson M; Van Camp B; Jernberg-Wiklund H; Vanderkerken K Clin Cancer Res; 2012 Apr; 18(8):2230-9. PubMed ID: 22392915 [TBL] [Abstract][Full Text] [Related]
15. The association of TP53 mutations with the resistance of colorectal carcinoma to the insulin-like growth factor-1 receptor inhibitor picropodophyllin. Wang Q; Wei F; Lv G; Li C; Liu T; Hadjipanayis CG; Zhang G; Hao C; Bellail AC BMC Cancer; 2013 Nov; 13():521. PubMed ID: 24182354 [TBL] [Abstract][Full Text] [Related]
16. Picropodophyllin induces downregulation of the insulin-like growth factor 1 receptor: potential mechanistic involvement of Mdm2 and beta-arrestin1. Vasilcanu R; Vasilcanu D; Rosengren L; Natalishvili N; Sehat B; Yin S; Girnita A; Axelson M; Girnita L; Larsson O Oncogene; 2008 Mar; 27(11):1629-38. PubMed ID: 17828296 [TBL] [Abstract][Full Text] [Related]
17. Oral picropodophyllin (PPP) is well tolerated in vivo and inhibits IGF-1R expression and growth of uveal melanoma. Economou MA; Andersson S; Vasilcanu D; All-Ericsson C; Menu E; Girnita A; Girnita L; Axelson M; Seregard S; Larsson O Invest Ophthalmol Vis Sci; 2008 Jun; 49(6):2337-42. PubMed ID: 18515579 [TBL] [Abstract][Full Text] [Related]
18. Role of the hypoxic bone marrow microenvironment in 5T2MM murine myeloma tumor progression. Asosingh K; De Raeve H; de Ridder M; Storme GA; Willems A; Van Riet I; Van Camp B; Vanderkerken K Haematologica; 2005 Jun; 90(6):810-7. PubMed ID: 15951294 [TBL] [Abstract][Full Text] [Related]
19. IGF-1 receptor inhibition by picropodophyllin in medulloblastoma. Ohshima-Hosoyama S; Hosoyama T; Nelon LD; Keller C Biochem Biophys Res Commun; 2010 Sep; 399(4):727-32. PubMed ID: 20692232 [TBL] [Abstract][Full Text] [Related]
20. The effects of JNJ-26481585, a novel hydroxamate-based histone deacetylase inhibitor, on the development of multiple myeloma in the 5T2MM and 5T33MM murine models. Deleu S; Lemaire M; Arts J; Menu E; Van Valckenborgh E; King P; Vande Broek I; De Raeve H; Van Camp B; Croucher P; Vanderkerken K Leukemia; 2009 Oct; 23(10):1894-903. PubMed ID: 19494837 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]